LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Search

Karyopharm Therapeutics Inc

Open

SectorHealthcare

9.15 3.39

Overview

Share price change

24h

Current

Min

8.8

Max

10

Key metrics

By Trading Economics

Income

-69M

-102M

Sales

-10M

34M

EPS

-5.69

Profit margin

-299.886

Employees

228

EBITDA

4.7M

-18M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+98.87% upside

Market Stats

By TradingEconomics

Market Cap

42M

199M

Previous open

5.76

Previous close

9.15

News Sentiment

By Acuity

50%

50%

162 / 346 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Karyopharm Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 maj 2026, 22:54 UTC

Earnings

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 maj 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 maj 2026, 23:51 UTC

Market Talk

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 maj 2026, 23:45 UTC

Market Talk

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 maj 2026, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

13 maj 2026, 23:17 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 maj 2026, 23:16 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 maj 2026, 23:15 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 maj 2026, 23:14 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 maj 2026, 23:02 UTC

Market Talk
Earnings

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 maj 2026, 22:59 UTC

Market Talk
Earnings

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 maj 2026, 22:24 UTC

Earnings

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 maj 2026, 22:23 UTC

Earnings

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 maj 2026, 22:23 UTC

Earnings

Xero FY International Revenue Growth 47%>XRO.AU

13 maj 2026, 22:22 UTC

Earnings

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 maj 2026, 22:19 UTC

Earnings

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 maj 2026, 22:19 UTC

Earnings

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 maj 2026, 22:18 UTC

Earnings

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 maj 2026, 22:16 UTC

Earnings

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 maj 2026, 22:15 UTC

Earnings

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 maj 2026, 22:15 UTC

Earnings

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 maj 2026, 22:13 UTC

Earnings

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 maj 2026, 22:12 UTC

Earnings

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 maj 2026, 22:11 UTC

Earnings

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 maj 2026, 22:11 UTC

Earnings

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 maj 2026, 22:10 UTC

Earnings

Xero Did Not Declare a Dividend>XRO.AU

13 maj 2026, 22:10 UTC

Earnings

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 maj 2026, 22:09 UTC

Earnings

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 maj 2026, 22:00 UTC

Earnings

Cisco to Shed Jobs for All-In AI Push -- Update

13 maj 2026, 21:11 UTC

Earnings

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Peer Comparison

Price change

Karyopharm Therapeutics Inc Forecast

Price Target

By TipRanks

98.87% upside

12 Months Forecast

Average 17.6 USD  98.87%

High 28 USD

Low 13 USD

Based on 6 Wall Street analysts offering 12 month price targets forKaryopharm Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

5.9501 / 7.66Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

No Evidence

Sentiment

By Acuity

162 / 346 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

help-icon Live chat